You are here

Eli Lilly

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

Fierce Pharma

emerging markets

Flag link:

Why Amgen, Lilly, J&J Are Interested In These Small Biotechs

Why Amgen, Lilly, J&J Are Interested In These Small Biotechs

Investors Business Daily

Bavarian Nordic

Biohaven Pharmaceuticals

Flag link:

EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point

EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point

Fierce Pharma

Boehringer Ingelheim

Flag link:

3,500 Job Cuts at Eli Lilly Signal Change in Focus

3,500 Job Cuts at Eli Lilly Signal Change in Focus

Xconomy

Flag link:

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

Endpoints

Flag link:

Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective

Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective

Marketwatch

clinical trials

Flag link:

Drugmaker Lilly to trim workforce by nearly 9 percent

Drugmaker Lilly to trim workforce by nearly 9 percent

Yahoo/AP

Flag link:

Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission

Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission

Xconomy

rheumatoid arthritis

Flag link:

Pharma Stocks That Could Move On New Data

Pharma Stocks That Could Move On New Data

Barron's

Bristol-Myers Squibb

European Society of Cardiology

Flag link:

Diabetes drugs must prove their value to payers, analysts say

Diabetes drugs must prove their value to payers, analysts say

Medical Marketing and Media

Flag link:

3 Most Promising Cancer Drugs in Late-Stage Development

3 Most Promising Cancer Drugs in Late-Stage Development

Motley Fool

advanced breast cancer

prostate cancer

Flag link:

Eli Lilly: Can Sales Grow Without M&A?

Eli Lilly: Can Sales Grow Without M&A?

Barron's

Flag link:

Eli Lilly’s odyssey to use a fake rule and fake news to protect bad patents

Eli Lilly’s odyssey to use a fake rule and fake news to protect bad patents

Stat

Flag link:

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Lilly's turn to pain gathers momentum

Lilly's turn to pain gathers momentum

BioPharma Dive

Flag link:

Lilly's acute migraine drug succeeds in late-stage study

Lilly's acute migraine drug succeeds in late-stage study

Yahoo/Reuters

clinical trials

Flag link:

CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana

CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana

Fierce Pharma

Boehringer Ingelheim

Flag link:

Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo

Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo

Fierce Pharma

Express Scripts

Flag link:

Eli Lilly CEO expects a Trump executive order on drug pricing this year

Eli Lilly CEO expects a Trump executive order on drug pricing this year

CNBC

Flag link:

Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals

Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals

Fierce Pharma

Flag link: